General Information of Drug (ID: DMLS39E)

Drug Name
Proparacaine Drug Info
Synonyms
Alcaine; Diocaine; Kainair; Ophthaine; Ophthetic; Paracaine; Prossimetacaina; Proximetacaina; Proximetacainum; Proxymetacaine; Proxymetacainum; Prossimetacaina [DCIT]; Proxymetacaine Hcl; Ak-taine; Alcaine (TN); Ocu-Caine; Proximetacaina [INN-Spanish]; Proxymetacaine (INN); Proxymetacaine [INN:BAN]; Proxymetacainum [INN-Latin]; Spectro-Caine; Ak-Taine (TN); Beta-(Diethylamino)ethyl 4-n-propoxybenzoate; BENZOIC ACID, 3-AMINO-4-PROPOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; 2-(Diethylamino)ethyl 3-amino-4-propoxybenzoate; 2-diethylaminoethyl 3-amino-4-propoxybenzoate; 3-Amino-4-propoxybenzoic acid 2-(diethylamino)ethyl ester
Indication
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [1]
Therapeutic Class
Anesthetics
Cross-matching ID
PubChem CID
4935
ChEBI ID
CHEBI:8485
CAS Number
CAS 499-67-2
TTD Drug ID
DMLS39E

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rilpivirine DMJ0QOW Human immunodeficiency virus infection 1C62 Approved [3]
Ropivacaine DMSPJG2 Anaesthesia 9A78.6 Approved [2]
Bupivacaine DM4PRFC Anaesthesia 9A78.6 Approved [2]
Tiapride DMN6CAG Alcohol dependence 6C40.2 Approved [4]
Tetracaine DM9J6C2 Spinal anesthesia MB40.3 Approved [5]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [6]
VX-150 DMGDB21 Neuropathic pain 8E43.0 Phase 2 [7]
DSP-2230 DM0WTMD Neuropathic pain 8E43.0 Phase 1 [8]
PF-01247324 DM93LMS Pain MG30-MG3Z Phase 1 [9]
VX-128 DMC8J0G Pain MG30-MG3Z Phase 1 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.8 (SCN10A) TT90XZ8 SCNAA_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7283).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
4 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
5 Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
6 Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
9 Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.